## Contents

**MINIREVIEWS**

4734  Inflammatory myofibroblastic tumor of the distal common bile duct: Literature review with focus on pathological examination  
*Cordier F, Hoorens A, Ferdinande L, Van Dorpe J, Creytens D*

4740  Probiotics and autoprobiotics for treatment of *Helicobacter pylori* infection  
*Baryshnikova NV, Ilina AS, Ermolenko EI, Uspenskiy YP, Suvorov AN*

4752  Plant-based diet and its effect on coronary artery disease: A narrative review  

## ORIGINAL ARTICLE

### Clinical and Translational Research

4763  Identification of survival-associated biomarkers based on three datasets by bioinformatics analysis in gastric cancer  
*Yin LK, Yuan HY, Liu JJ, Xu XL, Wang W, Bai XY, Wang P*

4788  High expression of autophagy-related gene *EIF4EBP1* could promote tamoxifen resistance and predict poor prognosis in breast cancer  
*Yang S, Hui TL, Wang HQ, Zhang X, Mi YZ, Cheng M, Gao W, Gong CZ, Li SN*

4800  Delineation of fatty acid metabolism in gastric cancer: Therapeutic implications  
*Fu Y, Wang B, Fu P, Zhang L, Bao Y, Gao ZZ*

4814  Mechanical analysis of the femoral neck dynamic intersection system with different nail angles and clinical applications  
*Wang Y, Ma JX, Bai HH, Lu B, Sun L, Jin HZ, Ma XL*

### Retrospective Cohort Study

4824  Development and validation of a predictive model for spinal fracture risk in osteoporosis patients  
*Lin XM, Shi ZC*

### Retrospective Study

4833  Risk prediction model for distinguishing Gram-positive from Gram-negative bacteremia based on age and cytokine levels: A retrospective study  
*Zhang W, Chen T, Chen HJ, Chen N, Xing ZX, Fu XY*

4843  Sudden death in the southern region of Saudi Arabia: A retrospective study  
*Al-Emam AMA, Dajam A, Alrajhi M, Aljaifi W, Al-Shraim M, Helaly AM*
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4852</td>
<td>Diagnostic value of preoperative examination for evaluating margin status in breast cancer</td>
<td>Liu P, Zhao Y, Rong DD, Li KF, Wang YJ, Zhao J, Kang H</td>
</tr>
<tr>
<td></td>
<td><strong>Prospective Study</strong></td>
<td></td>
</tr>
<tr>
<td>4865</td>
<td>Defining the awareness and attitude of the clinicians through pharmacovigilance in Turkey</td>
<td>Aydin OC, Aydin S, Guney HZ</td>
</tr>
<tr>
<td>4874</td>
<td>Predictive value of the trans-perineal three-dimensional ultrasound measurement of the pubic arch angle for vaginal delivery</td>
<td>Liang ZW, Gao WL</td>
</tr>
</tbody>
</table>

**CASE REPORT**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4883</td>
<td>Microwave ablation of solitary T1N0M0 papillary thyroid carcinoma: A case report</td>
<td>Dionísio T, Lajut L, Sousa F, Violante L, Sousa P</td>
</tr>
<tr>
<td>4890</td>
<td>Acute spinal subdural haematoma complicating a posterior spinal instrumented fusion for congenital scoliosis: A case report</td>
<td>Michon du Marais G, Tabard-Fougère A, Dayer R</td>
</tr>
<tr>
<td>4903</td>
<td>ABCB4 gene mutation-associated cirrhosis with systemic amyloidosis: A case report</td>
<td>Cheng N, Qin YJ, Zhang Q, Li H</td>
</tr>
<tr>
<td>4912</td>
<td>Metagenomic next-generation sequencing in the diagnosis of neurocysticercosis: A case report</td>
<td>Xu WB, Fu JJ, Yuan XJ, Xian QJ, Zhang LJ, Song PP, You ZQ, Wang CT, Zhao QG, Pang F</td>
</tr>
<tr>
<td>4920</td>
<td>Drug-coated balloons for treating de novo lesions in large coronary vessels: A case report</td>
<td>Zhang ZQ, Qin YR, Yin M, Chen XH, Chen L, Liang WY, Wei XQ</td>
</tr>
<tr>
<td>4926</td>
<td>Pretreatment with a modified St. Thomas’ solution in patients with severe upper limb injuries: Four case reports</td>
<td>Sun ZY, Li LY, Xing JX, Tong LC, Li Y</td>
</tr>
<tr>
<td>4932</td>
<td>Unexpected diffuse lung lesions in a patient with pulmonary alveolar proteinosis: A case report</td>
<td>Jian L, Zhao QQ</td>
</tr>
<tr>
<td>4937</td>
<td>Contrast-induced ischemic colitis following coronary angiography: A case report</td>
<td>Qiu H, Li WP</td>
</tr>
<tr>
<td>4944</td>
<td>Posterior pedicle screw fixation combined with local steroid injections for treating axial eosinophilic granulomas and atlantoaxial dislocation: A case report</td>
<td>Tu CQ, Chen ZD, Yao XT, Jiang YJ, Zhang BF, Lin B</td>
</tr>
</tbody>
</table>
Laryngospasm as an uncommon presentation in a patient with anti-N-methyl-D-aspartate receptor encephalitis: A case report

Wang L, Su HJ, Song GJ
ABOUT COVER
Editorial Board Member of World Journal of Clinical Cases, Kengo Moriyama, MD, PhD, Associate Professor, Department of Clinical Health Science, Tokai University School of Medicine, Tokai University Hachioji Hospital, Hachioji 1838, Tokyo, Japan. osaru3moving@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING
The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Hua-Ge Yu; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
World Journal of Clinical Cases

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

EDITORS-IN-CHIEF
Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE
July 16, 2023

COPYRIGHT
© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Laryngospasm as an uncommon presentation in a patient with anti-
N-methyl-D-aspartate receptor encephalitis: A case report

Lu Wang, Hong-Jun Su, Guan-Jie Song

**Abstract**

**BACKGROUND**

Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a rare autoimmune disorder. The symptoms of anti-NMDAR encephalitis include behavioral problems, speech problems, psychosis, seizures, and memory deficits, among others. However, laryngospasm is rare. We present the case of a patient with anti-NMDAR antibodies and severe laryngospasms.

**CASE SUMMARY**

The patient was a 15-year-old female with normal psychomotor development. She was initially admitted to our neurological intensive care unit with seizures. She received anti-epilepsy treatment, and the seizures disappeared. However, 2 wk later, she developed behavioral problems and speech impairment. Then, she developed severe laryngospasms, which were treated with intubation and a tracheotomy. Antibodies against the NMDAR were detected in the patient’s cerebrospinal fluid. Therefore, she was diagnosed with anti-NMDAR encephalitis. In addition, she received intravenously administered immunoglobulins, and methylprednisolone was administered. The patient’s symptoms gradually improved, and she was discharged from our hospital. Approximately 9 mo later, the patient could speak sentences, walk independently, and carry out activities of daily living independently. Through our case report, we highlighted laryngospasm as an uncommon presentation in patients with anti-NMDAR encephalitis.

**CONCLUSION**

Laryngospasm may be an uncommon clinical manifestation of anti-NMDAR encephalitis.

**Key Words:** Anti-N-methyl-D-aspartate receptor; Laryngospasm; Encephalitis; Epilepsy; Immunotherapy; Case report
Laryngospasms are uncommonly reported in anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Herein, we report a rare case of a patient with anti-NMDAR encephalitis with severe laryngospasms. The patient was treated with intubation and tracheotomy. In addition, she received intravenously administered immunoglobulins, and methylprednisolone was administered. Nine months later, the patient could perform activities of daily living independently. We highlighted that patients with anti-NMDAR encephalitis may present with fatal laryngospasms. Further study of fatal laryngospasms secondary to anti-NMDAR encephalitis may be necessary in the future.

INTRODUCTION
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune disorder that is mediated by anti-NMDAR antibodies. Anti-NMDAR encephalitis is characterized by behavioral problems, speech problems, psychosis, seizures, memory deficits, dyskiniasias, and autonomic and breathing dysregulation[1], with laryngospasm being uncommon. Anti-NMDAR encephalitis was first reported in 2007[2], and it predominantly affects young females with ovarian teratomas[3]. NMDAR is activated by glutamate and is expressed in the hippocampus and the forebrain. NMDAR plays a role in learning, memory, judgment, reality perception, and autonomic functions[4]. Intravenous pulse methylprednisolone and immunoglobulinls are first-line treatments. Some patients require artificial ventilation in the intensive care unit. Early diagnosis and timely immunotherapy are important for treating this disorder.

Here, we reported the case of a 15-year-old female patient with anti-NMDAR encephalitis and severe laryngospasms. We intend to raise awareness that patients with anti-NMDAR encephalitis may present with fatal laryngospasms.

CASE PRESENTATION
Chief complaints
A 15-year-old female presented with 3 d of seizures.

History of present illness
Three days prior, the patient had two episodes of tonic clonic seizures, with a loss of consciousness followed by falling and tonic muscle spasms, a gray face, and jerky movements of the arms and legs, which gradually disappeared after 2-3 min.

History of past illness
The patient had no history of epilepsy or psychosis.

Personal and family history
Both parents were healthy.

Physical examination
The patient’s body temperature was 36.5 °C, and her blood pressure was 116/80 mmHg. The findings of brain magnetic resonance imaging (MRI) and computed tomography (CT) were all initially normal. Electroencephalography (EEG) showed diffuse slow waves on basic activity. Our hypothesis was initially epilepsy, and we started treatment with levetiracetam (17 mg/kg/day), after which the seizures disappeared. Two weeks later, she started to experience behavioral problems and speech impairment, fearfulness, and auditory/visual hallucinations with an intermittent course during the day. On physical examination, the patient remained unresponsive to external stimuli. Then, she developed laryngospasms. When the laryngospasms occurred, there was an obvious tracheal pulling motion, accompanied by inspiratory stridor, and the patient’s oxygen saturation decreased from 97% to 70%. These episodes were initially self-limiting but later required aggressive pharmacological intervention, including intermittent intravenous diazepam injections at a dose of 10 mg and intravenous lobeline hydrochloride injections (3 mg/6 h). However, these drugs failed to suppress the laryngospasm episodes. Because the patient’s symptoms worsened, she underwent tracheal intubation and tracheotomy successively to help reduce airway irritation and reduce the administration of intravenous sedatives.
**Laboratory examinations**

All listed blood investigation results were within normal ranges. For example, her white blood cell count was within the normal range at 7.2 × 10⁹/L (normal range: 3.5-9.5 × 10⁹/L), glucose was 5.8 mmol/L (normal range: 3.9-6.1 mmol/L), her triglyceride level was 0.90 mmol/L (normal range: 0.00-2.26 mmol/L), gamma glutamyl transpeptidase was 37 U/L (normal range: 10-60 U/L), thyrotropin was 1.36 mIU/L (normal range: 0.55-4.78 mIU/L), and creatine phosphokinase was 51 U/L (normal level: 0-171 U/L). Lumbar puncture examination of the cerebrospinal fluid (CSF) revealed a pressure of 200 mmH₂O (normal range: 80-180 mmH₂O). CSF analysis revealed the following: 12 nucleated cells/mL (normal level: 0-5 nucleated cells/mL); glucose 3.8 mmol/L (normal range: 2.5-4.5 mmol/L); protein 0.38 g/L (normal range: 0.15-0.45 g/L); and chloride 116.7 mmol/L (normal range: 116.0-130.0 mmol/L). NMDAR antibodies were detected in the CSF.

**Imaging examinations**

The findings of brain MRI and CT were all initially normal. However, upon re-examination 2 wk later, a cranial MRI revealed abnormally high signals in the left frontotemporal parietal occipital cortex and subcortical area on T2-weighted images and fluid-attenuated inversion recovery images (Figure 1). A 4-h video electroencephalogram showed nonspecific slow activity without epileptic discharge. Chest CT, pelvic and abdominal color ultrasound, and MRI did not reveal any tumors, including teratomas.

**FINAL DIAGNOSIS**

The patient was diagnosed with anti-NMDAR encephalitis.

**TREATMENT**

The patient received glucocorticoids and human immunoglobulin (IVIG) treatments. She was started on a 3-d course of intravenous methylprednisolone (30 mg/kg/day), followed by oral administration of prednisone (2 mg/kg/day, weaned over 3 mo) and intravenous IVIG 400 mg/kg/day for 5 d. Four weeks later, the frequency of laryngospasm gradually decreased, and the clinical symptoms gradually decreased. The patient’s psychiatric and neurological symptoms were resolved. The patient was transferred to the rehabilitation unit after 3 mo.

**OUTCOME AND FOLLOW-UP**

Presently, the patient has been under follow-up for 9 mo. She is now able to speak in sentences, walk independently, and perform activities of daily living independently. She has had no seizures or abnormal body movements.

**DISCUSSION**

Anti-NMDAR encephalitis is an autoimmune neuropsychiatric disorder[2]. Encephalitis is associated with the production of autoantibodies directed toward NMDAR, a protein involved in synaptic plasticity and memory function. The clinical manifestations of anti-NMDAR encephalitis are complex and vary in severity. Most patients present with prodromal symptoms, including fever, nausea, headache, and diarrhea. Within 2 wk, patients usually develop a multistage illness that progresses from psychosis, seizures, speech impairment, and memory deficits to a state of unresponsiveness with catatonic features often associated with autonomic and breathing instability[5]. Approximately 60% of cases with anti-NMDAR encephalitis have tumors, and teratomas are the most commonly associated tumors[6].

No prodromal symptoms or tumors were found during the clinical diagnosis or treatment of the patient. This patient showed epilepsy onset but exhibited severe laryngospasms, which represent an uncommon symptom of anti-NMDAR encephalitis and a difficult problem during treatment. Laryngospasm may result from the spread of tonic discharges into the cortex (lateral motor nucleus and anterior insula) that controls laryngeal movement or a marked increase in vagal tone[7]. It has been speculated that laryngospasm in patients with anti-NMDAR encephalitis may be related to epileptic activity[8]. We speculate that the pathogenesis of anti-NMDAR encephalitis-related laryngospasm may be similar to the abovementioned mechanism, but more studies are needed to confirm this.

It has been reported that EEG findings either at the onset or during the course of the disorder are abnormal in more than 90% of patients[9]. The sensitivity of cranial MRI is lower, being positive in less than 55% of patients[3]. EEG showed diffuse slow waves of basic activity in our patient. Her early cranial MRI findings were nonspecific. As the disorder progresses, T2-weighted images and fluid-attenuated inversion recovery can reveal abnormal signals in the left frontotemporal parietal occipital cortex and subcortical areas.

The first-line treatment drugs are high and early doses of glucocorticoids and IVIG[10]. If first-line treatment is ineffective, second-line treatment (cyclophosphamide or rituximab) is often effective. With immunotherapy and in cases of neoplastic tumor removal, this disorder is reversible. Early initiation of treatment is associated with a more favorable clinical outcome. Bortezomib treatment showed disease remission or clinical improvement in patients with resistance or...
delayed treatment response to standard immunosuppressive and B-cell-depleting drugs (corticosteroids, IVIG, immunoadsorption, plasma exchange, rituximab, cyclophosphamide)[11]. With proper treatment, most patients can slowly obtain a full or a nearly full recovery. However, recovery may take 2 years or longer, and not all patients can return to former levels of motor and cognition function. In the present study, the patient was treated with glucocorticoids and IVIG. She could independently perform activities of daily living several months later.

CONCLUSION

Laryngospasm may be an uncommon clinical manifestation of anti-NMDAR encephalitis, and it can be suggestive of a critical illness and the possibility of sudden death. Early identification and early aggressive treatment can affect the prognosis of the disorder.

ACKNOWLEDGEMENTS

We would like to express our appreciation to editors and reviewers for suggesting how to improve our paper.

FOOTNOTES

Author contributions: Wang L contributed to the intellectual content and drafted the manuscript; Su HJ was responsible for the acquisition and interpretation of the data; Song GJ prepared the legends, updated the literature, and interpreted the results; All authors made a substantial contribution to the preparation of the manuscript and read and approved the final version of the manuscript.

Informed consent statement: Informed written consent was obtained from the patient and her parents for the publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China
REFERENCES


